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Introduction
According to the Journal of 
Anesthesia and Intensive Care, 
Malignant Hyperthermia (MH) is an 
uncommon disorder of skeletal 
muscle, with autosomal dominant 
inheritance triggered almost 
exclusively by potent inhalational 
agents and suxamethonium (Chan, 
Bulger, Stowell, Gillies, Langton, 
Street, and Pollock, 2017).  Although 
it is rare, it is a true medical 
emergency which can lead to death 
if left untreated.  Mostly anesthesia 
medications trigger the response so 
it is imperative the anesthesia 
providers along with the 
postoperative nurses know the signs 
and symptoms that trigger 
malignant hyperthermia.  It is a 
hypermetabolic state triggered by 
an abnormality of calcium release or 
reuptake by the sarcoplasmic 
reticulum with muscle contraction.  
The incidence of MH in adults is one 
in every 50,000 to 100,000 and 
children is one in every 300,000 to 
500,000 cases (Chan et al., 2017).  
Since MH occurs in genetically 
predisposed individuals, one must 
go through an invasive muscle 
biopsy procedure to get diagnosed.  
The test is very expensive and has a 
high false positive result.  This topic 
was chosen due to my future 
interest as a practicing nurse 
anesthetist.  Researching MH will 
prepare me and make me more 
aware as an anesthesia provider. 




Medical personnel should be 
aware and recognize the signs and 
symptoms of MH.  The cardinal 
sign of MH is hyperthermia, which 
is relatively a late sign.  MH can 
occur very suddenly with muscle 
rigidity or gradually and not show 
the signs till in the post-operative 
unit.  
Signs and Symptoms include:
-Tachyarrhythmia’s in 96% of 
cases
-Tachypnea in 85% due to rapidly 
rising carbon dioxide level
-Acidosis in 80% due to lactic acid 
and heat
-Oxygen saturation levels drop 
during normal ventilation
-Generalized muscle rigidity in 
80% is one of the earliest signs 
(Hommertzheim & Steinke, 2006)
Therefore many complications 
can occur due to the profound 
impact on the body.  Severe 
complications such as metabolic 
acidosis, bowel ischemia, 
compartment syndrome of the 
limbs, vital organ dysfunction, 
acute renal failure, and 
disseminated intravascular 
coagulation.  Other less severe 
symptoms include muscle 
weakness, lightheadedness, and 
difficulty swallowing 
(Hommertzheim & Steinke, 2006).
Underlying 
Pathophysiology
MH is a hypermetabolic state 
triggered by an abnormality of calcium 
release or reuptake by the 
sarcoplasmic reticulum with severe 
muscle contraction.  In genetically 
predisposed individuals the triggering 
event resides in the skeletal muscle at 
the level of calcium when it transfers 
into the muscle cell.   Therefore the 
influx of calcium into the cell leads to 
hypermetabolism which increases 
carbon dioxide production, increases 
oxygen consumption, and increases 
sympathetic activity (Hommertzheim 
& Steinke, 2006).   
-The most common mutation is found 
in the RYR1 gene on chromosome 19 
that regulates the calcium pathway 
for the sarcoplasmic reticulum.  The 
distribution of the mutation is varied 
among ethnic groups (McGoldrick, 
2017).
-The increase or surge of intracellular 
hypercalcemia activates a cascade of 
metabolic pathways that deplete ATP, 
cause acidosis, membrane 
destruction, and cell death 
(McGoldrick, 2017).
-Testing can be performed to 
determine susceptibility of MH with a 
caffeine halothane contracture test 
(CHCT).  The CHCT test requires 
invasive muscle biopsy from the thigh.  
Only six centers in the United States 
are approved for testing.  A patient 
must travel to a center in order to get 
tested which is generally not covered 
by insurance at $6,000 
(Hommertzheim & Steinke, 2006).
Significance of Pathophysiology
-Knowing the pathophysiology of MH allows individuals to recognize the 
signs and symptoms of MH faster.  Also knowing the mechanism of action 
allows for treatment.  Two known triggering agents are succinylcholine and 
halogenated volatile anesthetics (Hommertzheim & Steinke, 2006). 
- Other triggers include butyrophenones, phenothiazines, various atypical 
anti-psychotics, anti-dopaminergic drugs, and abrupt withdrawal of anti-
Parkinson’s drugs (McGoldrick, 2017).
-Stop the trigger agent immediately and active the MH team to get help to 
quickly stop the crisis to prevent it from progressing to life-threatening 
conditions.  
Implications for Nursing Care
The anesthesia staff along with the 
registered nurses working in the 
postoperative unit must know the 
response plan for an MH event.  
Chances for a successful outcome 
will increase with a rapid, accurate 
diagnosis and a coordinated, swift, 
multidisciplinary team to deliver 
the appropriate treatment (Dirksen, 
Van Wicklin, Mashman, Neiderer, 
Merritt, 2013).  Therefore, proper 
education and training is imperative 
to all the necessary team members 
based on the organizations
environment.  Practice through 
simulation and mock drills are 
essential to ensure the staffs roles 
are defined during a MH crisis.  
Many facilities have a designated 
emergency cart solely responsible 
for a MH crisis.  Staff must know 
where the carts are located and 
know how to use the equipment 
within the carts.  Perioperative 
nurses also screen patients prior to 
anesthesia and maybe able to 
uncover red flags such as a prior 
occurrence or known family 
member who has experienced MH. 
-If and MH event occurs the 
procedure should be stopped 
immediately unless emergent.  If 
the procedure must continue the 
anesthesia team is responsible for 
discontinuing all triggering 
anesthetics and begin the 
treatment for MH.  Treatment 
begins by hyperventilating the 
patient with 100% oxygen and 
administering a dose of dantrolene 
sodium.  Dantrolene is a skeletal 
muscle relaxant that depresses 
muscle contraction by decreasing 
intracellular calcium concentration 
(National Institute s of Health, 
2018).  Electrolyte replacement and 
monitoring will have to be 
corrected.  The patient would most 
likely be transferred to the 
intensive care unit for monitoring 
for the next day or two for 
observation.     
.
Conclusion
-MH is rare genetic ailment that is a 
life-threating condition when 
provoked by the administration of 
anesthetic agents.
-The earliest signs of MH are 
generally non-specific, which can 
make MH very difficult to diagnose 
by even experienced medical 
professionals (Issak & Stiegler, 
2016).
-Simulation and mock drills are 
necessary to all anesthesia providers 
and nurses know how to monitor 
and treat a patient if MH develops.
-Testing is expensive and not 
convenient for a majority of the 
population. 
-Before the introduction of 
dantrolene, the mortality of MH was 
84%.  Now with proper monitoring 
and education the mortality has 
been reduced to 9% (Chan et. al, 
2017).
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